Is weight-based IV dosing of trastuzumab preferable to SC fixed-dose in some patients? A systematic scoping review

Trastuzumab, a key treatment for HER2-positive breast cancer, is available in weight-based IV and fixed-dose (600 mg) SC formulations. While the Phase 3 HannaH trial indicated non-inferiority of the SC formulation, there is some concern that the target plasma concentration may not be reached in over...

Descripción completa

Detalles Bibliográficos
Autores principales: Kolberg, Hans-Christian, Jackisch, Christian, Hurvitz, Sara A., Winstone, Julie, Barham, Helen, Hanes, Vladimir, Courmier, Delphine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8044716/
https://www.ncbi.nlm.nih.gov/pubmed/33799233
http://dx.doi.org/10.1016/j.breast.2021.03.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8044716/
https://www.ncbi.nlm.nih.gov/pubmed/33799233
http://dx.doi.org/10.1016/j.breast.2021.03.003

Ejemplares similares